Best Startup
At Best Startup UK we track over 130,000 UK startups and over 500,000 people who hold key positions in these companies. We use this directory of startups to highlight top employees, founders and board members we think deserve more appreciation than they are currently getting.
This list showcases the top United Kingdom based CEO’ operating in the Biotechnology space. If you think a CEO’ is missing from this list, feel free to contact our editor on editor@beststartup.co.uk.
The individuals on this list have been included because of exceptional performance in one of the following categories:
- Innovation – Operating as a key part in an extremely innovative business or startup.
- Growth – Operating as a key figure in the growth and upscale of a market leading business or startup.
- Management – Showing exceptional management skills.
- Societal impact – Putting their business on the map for their positive societal or environmental impact.
Our Data – We source our data from OSINT (open source intelligence) and public directories such as Companies House UK, Crunchbase, SemRush and many more. The data from these sources should be treated with a degree of caution and verified yourself.
Valentina Milanova
Founder and CEO of Daye
Valentina previously worked with Techstars as a Business Development Associate. She is currently looking after the AI portfolio at Founders Factory – launching 200 businesses in the next five years! Before entering the startup and VC worlds, Valentina studied law and worked as a technology correspondent for large international publications.
Follow Valentina Milanova:
About Daye: Daye creates category-defining products and services that set a new standard for medical research and scientific innovation.
_______
Sara Murray
Founder & Chief Executive Officer of Buddi
Sara Murray (M.A. Oxon) is a serial entrepreneur. She founded Ninah Consulting, which uses proprietary software to advise clients, including GSK and Coca-Cola, on marketing effectiveness, and sold it to Publicis Groupe. In 1999, Sara founded Inspop, which owns the brand Confused.com. She built and sold the online company to the Admiral Group. She was a non-executive Director of Schering Health Care and a founding board member of Seedcamp. Sara won the Entrepreneur of the Year Award 2009 and sits on the Technology Strategy Board Governing Board. Sara was awarded an OBE for services to Entrepreneurship and Innovation in the Queen’s Birthday Honours 2012 and is a qualified helicopter pilot.
Follow Sara Murray:
About Buddi, Confused.com: Buddi is an innovative, high-growth and british technology company that develops location and health monitoring technologies.
Kevin Lee
Chief Executive Officer of Bicycle Therapeutics
Kevin Lee, Ph.D., MBA, is chief executive officer of Bicycle Therapeutics. Kevin joined Bicycle Therapeutics from Pfizer, where he served as senior vice president and chief scientific officer of the Rare Disease Research Unit. In that role, he held responsibility for more than 20 novel programmes across the full spectrum of research and development, established Pfizer’s rare disease strategy, conceptualized and implemented the company’s gene therapy strategy with the creation of the Genetic Medicine Institute and founded the Rare Disease Research Consortium. Prior to joining Pfizer, Kevin worked at GlaxoSmithKline (GSK) and, in addition to leading the formation of multiple strategic commercial and academic partnerships, he led epigenetics research and was responsible for the creation of the EpiNova Discovery Performance Unit. Before joining GSK, he lectured at Warwick University Medical School and founded Cambridge Biotechnology (acquired by Biovitrum) and Neurosolutions. Kevin studied pharmaceutical sciences at Nottingham University followed by a Ph.D. in pharmacology at Cambridge University. He undertook postdoctoral training as a Wellcome Trust International Prize Fellow before joining the Parke Davis Research Unit in Cambridge, U.K. Kevin is an author on over 100 peer-reviewed scientific publications, has an MBA from Warwick Business School and has been awarded an honorary Chair in Molecular Pharmacology from the University of Warwick.
Follow Kevin Lee:
About Bicycle Therapeutics: Bicycle Therapeutics is developing a technology for the creation of new generation biotherapeutics.
Emma Sceats
CEO of Isogenica
Dr Sceats joined CN Bio Innovations in 2010 as Commercial Manager to spearhead the organisation’s sales, marketing and business development activities. She has led sales and partnering initiatives with major pharmaceutical organisations and overseen academic research and licensing programs, including with the Massachusetts Institute of Technology (MIT) that have led to the development of the company’s leading products. Dr Sceats was promoted to Chief Operating Officer in May 2013 with responsibility for the day-to-day running of the company, focussing on delivering the objectives of company investors. Dr Sceats holds degrees from Oxford and Bristol Universities (UK) and the Massachusetts Institute of Technology, where she studied Chemistry. Her previous roles include working as a research scientist at E.I. DuPont de Nemours (Wilmington, DE, USA) and in intellectual property management and licensing for the University of Oxford.
Follow Emma Sceats:
About Isogenica: Isogenica operates a range of discovery platforms supported by state-of-the-art methodologies for identifying antibody and peptide ligands.
Siro Perez
Co-Founder & CEO of Molecular Warehouse
Follow Siro Perez:
About IP Group, Kira Biotech, Molecular Warehouse: Molecular Warehouse is creating a world where most diseases are prevented, by giving people the power of molecular diagnostics and mHealth.
Emmanuel Ligner
President & CEO, Life Sciences of GE Healthcare
Emmanuel joined GE Healthcare in April 2008, following its acquisition of Whatman International Plc. Since 2008, Emmanuel has held various positions in GE Healthcare Life Sciences. Working both in the UK and in the US, he managed the North America BioProcess business. In January 2012, Emmanuel took charge of the Commercial part of the then Life Sciences business, across EMEA, later expanding his role to include global commercial leadership of BioProcess. In January 2016, Emmanuel was name General Manager of the Core Imaging business which he held until he was named President and CEO of Life Sciences In July 2017. Emmanuel first entered the biopharma industry in Japan, joining Ostuka Pharmaceutical International Ltd as a Medical Representative in Tokyo. After five years in Ostuka in various roles, Emmanuel joined Abbott Japan, occupying positions such as Marketing Director Diagnostic Division and Commercial Director Diabetes Care Division. After 10 years in Japan, Emmanuel moved to the UK as Vice President Sales & Marketing Europe for Whatman International Plc.
Follow Emmanuel Ligner:
About Cytiva, GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Jan Makela
President and CEO, Imaging at GE Healthcare of GE Healthcare
Jan Makela is the President & CEO of GE Healthcare Global Services. Appointed in December 2017, he oversees the global development and execution of GE Healthcare’s service solutions and operations around the globe.
Follow Jan Makela:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Kieran Murphy
President & CEO of GE Healthcare
Kieran Murphy is President and CEO of GE Healthcare, a $20 billion business unit of General Electric that provides transformational medical technologies and solutions to the global healthcare industry. GE Healthcare supports customers in over 100 countries with a broad range of services and systems, from diagnostic imaging and healthcare IT through to molecular diagnostics and life-sciences. Prior to this, Kieran was President and Chief Executive Officer of GE Healthcare Life Sciences, a $3.7 billion molecular medicine business that provides a broad range of industry-leading technologies and services for drug discovery, pre-clinical and clinical development and biopharmaceutical manufacturing, as well as molecular tools for diagnostics, therapy selection and treatment monitoring in patient care. Kieran was appointed CEO in May 2011 and oversaw significant revenue growth and geographic expansion of the molecular medicine business. Kieran joined GE Healthcare in 2008 from Whatman plc, a $230 million global supplier of filters and membranes for laboratory research, life sciences and medical diagnostic applications. Kieran has over twenty years’ experience in the global life sciences and biotechnology industry, beginning his career with Janssen Pharmaceutical, a division of Johnson and Johnson, followed by leadership roles with Mallinckrodt, veterinary medicines provider Vericore, Novartis, Adprotech, ML Laboratories and Innovata plc.
Follow Kieran Murphy:
About GE Healthcare: GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care.
Gordon Sanghera
Chief Executive Officer, Co – founder of Oxford Nanopore Technologies
Gordon Sanghera was co-founder of Oxford Nanopore, together with Hagan Bayley and IP Group. He was appointed CEO in June 2005 having acted as a consultant since February 2005 whilst the Company was established. He brings over 15 years experience in the design, development and global launch of novel point-of-care biosensor devices. At Abbott Laboratories, Dr Sanghera held both UK and US Director level positions, including Research Director and Manufacturing Process Development Director. Before its acquisition by Abbott, Gordon led the R&D of Medisense Inc. where he was instrumental in the launch of several generations of blood glucose biosensor systems for the consumer and medical markets. He has also developed and validated market production processes to meet with the regulatory requirements for USA and Europe. Gordon has a DPhil in biosensor technology and a degree in Chemistry.
Follow Gordon Sanghera:
About Oxford Nanopore Technologies: Oxford Nanopore Technologies develops nanopore-based electronic systems for analyzing single molecules, including DNA, RNA, and proteins.
Benjamina Bollag
Founder & CEO of HigherSteaks
Benjamina is the CEO of London-based food tech start-up Higher Steaks, which she founded in 2017. Previously, Benjamina co-founded a London-based B2B electronics company selling to FTSE500 companies. Benjamina has also worked at Israeli 3D printing company, Stratasys, at the digital marketing division of PepsiCo’s joint venture with Strauss and was the lead developer an ed-tech startup. Benjamina holds a Master of Chemical Engineering from the Imperial College, where she completed a project focusing on the design of a peptide plant, conducting a lab-based research on synthesis and liquid exfoliation of graphitic carbon nitride
Follow Benjamina Bollag:
About HigherSteaks, Zestful: HigherSteaks is about providing with that juicy, tender, and delicious meat they love but without harming their health, planet, and animals.
John Lucas
Chief Executive Officer of Oxford Cannabinoid Technologies
John is a pharmaceutical executive with over 20 years of experience, having previously held executive level management positions at Cizzle Biotechnology (as CEO), Silence Therapeutics (as General Counsel) and Ilika Plc (Vice President, Intellectual Property) with other experience at the National Cancer Institute and Boehringer Ingelheim Pharma. John has also run his own consulting business where he assisted clients with business and legal/patent matters in biotech-pharma. His experience includes deal-making, corporate and product strategy, operations, and patents. John also has a wide range of subject matter experience including small molecule pharmaceuticals (including cannabinoids), RNA therapy, biologics, and diagnostics. John holds a law degree (JD) from George Washington University, a doctorate in molecular genetics from The Ohio State University, and a Master’s and Undergraduate degree in microbiology from Ohio University.
Follow John Lucas:
About Oxford Cannabinoid Technologies: OCT is a biopharmaceutical company established to combine cannabinoid medicine with world class scientific research.
Alex Blyth
CEO of LIfT BioSciences
Serial entrepreneur with 15 years’ experience in commercialising biopharma assets and strategy consulting, having advised teams and led the strategic planning on the launch of over 50 assets. Founded the company after losing his mother to Pancreatic Cancer.
Follow Alex Blyth:
About LIfT BioSciences, NGX: LIfT BioSciences is a socially-minded Biotech start-up that develops a portfolio of potentially life-saving immuno-oncology cell therapies.
George Goldsmith
Executive Chairman, Chief Executive Officer & Co-Founder of COMPASS Pathways
George is a serial entrepreneur with significant experience in pharmaceutical regulation. George’s early training and experience was a multi-disciplinary blending of cognitive psychology, clinical psychology and computer science.His first company, The Human Interface Group, was a pioneer in collaborative software and acquired by Lotus Development. George led the Lotus Institute and developed software and services to support high-performance, distributed teamwork. George then created TomorrowLab, which provided strategic guidance to internet businesses in the late 1990s. At the same time, he became a senior advisor to McKinsey & Company’s leadership, and eventually joined McKinsey as CEO of TomorrowLab@McKinsey. Subsequently, as a member of the Young Presidents Organisation (YPO) and its International Board of Directors, George founded YPO Networks. In 2002, George founded Tapestry Networks, an organisation committed to improving leadership performance and governance effectiveness in regulated sectors. He still serves as Tapestry Networks’ Non-Executive Chairman. George also serves on the board of directors for AnaBios, a company redefining drug discovery. He and his wife, Ekaterina Malievskaia MD, live in London.
Follow George Goldsmith:
About COMPASS Pathways: Compass Pathways is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health.
Avi Lasarow
CEO Europe, Middle East & Africa of Prenetics
Avi Lasarow is a multiple award-winning South African entrepreneur referred to by the media as ‘a lifestyle genetics pioneer’ known for his work associated with DNA testing. Avi is currently founder and CEO of genetic testing company DNAFit Life Sciences, which conducted the worlds 1st peer-reviewed and published clinical trial using both genetics and exercise interventions. In 2011 he became the youngest person to be appointed Honorary Consul for South Africa to the United Kingdom by His Excellency President Jacob Zuma. Avi was recently named African Businessman of the year in London at the African Enterprise Awards, his company DNAFit has won numerous awards, including the Lloyd’s Bank National Business Award for Innovation of the Year in 2015, winner at the UKActive Flame Awards and an award for Innovation at the South African Chamber Awards. Most recently, DNAFit was named as one of Fast Company’s Most Innovative in the field of Data Science.
Follow Avi Lasarow:
About DNAFit, Prenetics: Prenetics is a genetic and diagnostic health testing company that helps identify health risks with the use of a DNA sequencing technology.
Henrik Hagemann
CEO and Co-Founder of Puraffinity
Follow Henrik Hagemann:
About Puraffinity, Tech London Advocates: Puraffinity develops precision materials to target chemicals, with an initial focus on PFAS in water
Clive Dix
CEO of C4X Discovery
Clive Dix is the Chief Executive Officer at C4X Discovery Holdings plc. since November 2015. Clive has over thirty years’ experience in the pharmaceutical and biotechnology industries. Clive was Co-Founder and Chief Executive Officer of PowderMed Limited, which was sold to Pfizer Inc. in 2006 and Co-Founder and Chief Executive Officer of Convergence Pharmaceuticals Limited, which was sold to Biogen Inc. in 2015. Clive’s other previous roles include: Senior Vice President of Research and Development at PowderJect Pharmaceuticals plc. sold to Chiron in 2003, Chairman of the UK BioIndustry Association, Chairman of the Board of Directors of Crescendo Biologicals Limited and Chairman of the Board of Directors of Auralis Limited (acquired by ViroPharma Inc). Following post-doctoral roles and a period at Ciba-Geigy AG (now Novartis AG), Clive joined GlaxoWellcome plc. where he became UK Research Director. Clive is currently an Executive Chairman of the Board of Directors at C4X Discovery Holdings plc., Chairman of the Board of Directors at Touchlight Genetics Limited. Clive is a past Chairman of the Board of Directors of Calchan Ltd. Clive earned his B.Sc. and Ph.D. degrees in Pharmacology from University of Leeds.
Follow Clive Dix:
About C4X Discovery: C4X Discovery brings a new dimension to drug discovery. Using its unique NMR-based technique to determine 3D molecular.
Stephan Tual
Founder, CEO of 3 Billion Pairs Genetic
Stephan Tual is the Founder & CEO at 3 Billion Pairs Genetics Ltd. & he attended Institut Franco-Américain de Management in 1995.
Follow Stephan Tual:
About 3 Billion Pairs Genetic: 3 Billion Pairs Genetic is a biotechnology based company.
Maria Chatzou Dunford
CEO and Co-Founder of Lifebit
Dr. Maria Chatzou, CEO of Lifebit, is a biotech innovator and a proud geek, expert in bioinformatics, medical informatics and high performance computing. She is also a passionate entrepreneur and has founded two companies, Innovation Forum Barcelona and Techstars-backed Lifebit. Prior to Lifebit, she was a researcher at the Centre for Genomic Regulation, in Barcelona, where she was designing and deploying tools and methods that facilitate the analysis of Big Biomedical Data, allow for biological discoveries, and promote personalised medicine. She was part of the developing team of Nextflow, a programming framework that is revolutionising the computational analysis of genomic data and setting the foundations for personalised medicine computational analyses. Maria is also a frequent industry speaker and has spoken in many international conferences on the subjects of docker containers, genomics workflows, the computational challenges of personalised medicine, AI and HPC in genomics, women in leadership, entrepreneurship, science ventures, among many other topics.
Follow Maria Chatzou Dunford:
About Lifebit: Lifebit CloudOS is the intelligent genomics platform that is the industry standard for unified, secure research over distributed big data.
Dipankar Bhattacharjee
President & CEO: Generics Europe of Teva Pharmaceutical Industries
Mr. Dipankar Bhattacharjee was appointed President and CEO, Generics Europe in April 2013. Mr. Bhattacharjee joined Teva as Chief Executive Officer, Teva UK Limited in 2009. Prior to joining Teva, he served 15 years at Bausch + Lomb in various senior roles, including Vice President, Commercial in both Europe and Asia-Pacific regions, and Corporate Vice President and President, Asia Pacific Region. Mr. Bhattacharjee began his career at Nestlé SA and Bank of America. Mr. Bhattacharjee received a BA in Economics from St. Stephens College, University of Delhi, and a Masters degree in Management Studies from Jamnalal Bajaj Institute of Management Studies, University of Mumbai.
Follow Dipankar Bhattacharjee:
About Teva Pharmaceutical Industries: Teva Pharmaceutical Industries is a pharmaceutical company specializing in the development, production and marketing of generic.
Gregg Sando
Founder & former Chief Executive Officer of Kuur Therapeutics
Gregg Sando is the founder and CEO of Cell Medica. After a career in investment banking based both in London and New York, he completed his Immunology MSc degree at the medical school of Imperial College. Recognizing the significant progress taking place in the field of cellular immunotherapy, Gregg formed Cell Medica in cooperation with a small group of the leading clinicians and immunologists who were pioneering this new mode of medical treatment. (B.A. Biochemistry, Harvard University; M.B.A. University of Chicago; MSc Immunology, Imperial College London).
Follow Gregg Sando:
About Kuur Therapeutics: Kuur Therapeutics is committed to transforming the lives of patients with cancer & is leading the development cell therapies.
Niall Dunne
CEO of Polymateria
Niall Dunne is the Chief Executive Officer of Polymateria.
Follow Niall Dunne:
About Polymateria: Polymateria is a London-based startup advancing science to help nature deal with plastic pollution.
Tom Simmons
Founder & CEO of Supplant
Tom has over 10 years of experience in carbohydrate biochemistry. He formerly held fellowships at the University of Cambridge and at the World Economic Forum and has advocated sugar reduction initiatives through Sky News and Channel 4 television appearances.
Follow Tom Simmons:
About Cambridge Judge Business School, Supplant: Supplant is a biotechnology platform that makes sugar substitutes.
Joanna Shields
CEO of BenevolentAI
Joanna Shields (Baroness Shields OBE) is a tech industry veteran with a successful track record building some of the world’s best-known companies. Her career spans over 30 years and has focussed on harnessing the power of technology to drive change that improves connectivity, humanity and society. Joanna is currently Chief Executive Officer of BenevolentAI, a world leader in the development and application of artificial intelligence and machine learning to understand the underlying causes of disease, accelerate drug discovery and develop new and more effective medicines. Prior to joining BenevolentAI, Joanna served as the UK’s first Minister for Internet Safety and Security, Under Secretary of State, Special Advisor on the Digital Economy, and Chair & CEO of TechCityUK. Prior to her government service, Joanna held executive roles at Google, Facebook, Bebo/Aol, Decru, RealNetworks, Veon and EFI and served as a non-executive director of the London Stock Exchange Group. Joanna founded WePROTECT.org, a multi-stakeholder global alliance working to protect children from online abuse and exploitation. She is a member of the Council on Foreign Relations, the Transatlantic Commission on Election Integrity and the Child Dignity Alliance. She is also a Commissioner on the Oxford Commission on AI & Good Governance (OxCAIGG) and sits on the Global Partnership on Artificial Intelligence (GPAI) as the UK nominated expert on an AI-enabled COVID response. In November 2020, she was elected Co-Chair of the GPAI Steering Committee and Chair of the GPAI Multi-stakeholder Expert Group Plenary. In 2014, Joanna was appointed OBE for services to digital industries and voluntary service to young people and made a Life Peer of the House of Lords.
Follow Joanna Shields:
About BenevolentAI, UK House of Lords: BenevolentAI is a developer of artificial intelligence and computational medicine technologies.
Mark Kotter
Founder/CEO of bit.bio
Mark Kotter is the founder and CEO of bit.bio.
Follow Mark Kotter:
About bit.bio: Bit.bio specializes in the fields of coding and biology that determine the identity of every human cell.
Tom Henley
Founder and CEO of Empyrean Therapeutics
Tom Henley is the founder and CEO of Empyrean Therapeutics.
Follow Tom Henley:
About Empyrean Therapeutics: Empyrean Therapeutics develops next generation cell therapies to enable global and affordable cures for diseases.
Greg Bailey
CEO of Juvenescence
Dr. Gregory H. Bailey is a Managing Partner at Palantir Group, Inc. Dr. Bailey is the Co-founder of Ascent Healthcare Solutions; VirnetX Inc. (AMEX:VHC) and Duramedic Inc. He was also the initial public financier and an independent director of Medivation, Inc. (NASDAQ:MDVN), from 2005 to December 2012. Dr. Bailey served as the Managing Director and co-Head of Life Sciences at MDB Capital Group LLC from May 2004 to January 2007. Previously he served as Life Sciences Analyst at Participating Capital, Corp. He has served on the board of directors of multiple public companies. Dr. Bailey has Medical Doctorate from the University of Western Ontario and practiced medicine as an emergency physician for ten years.
Follow Greg Bailey:
About Juvenescence, Portage Biotech: Juvenescence is a biotech company that develops therapies and products to modify aging and help people live longer.
Bo Jing
CEO of ONI
Follow Bo Jing:
About ONI: ONI is a pioneer of super-resolution microscopy, making this advanced technology accessible to new generations of researchers.
Aron Rachamim
Founder & CEO of Senzo
Aron Rachamim is committed to changing the world by putting healthcare information into everyone’s hands. A serial entrepreneur, scientist, and experienced leader, Aron aims to apply pioneering technologies to improve people’s quality of life. His expertise and passion for the science of microfluidics builds on his background in life sciences, physics, and engineering. His company Orphidia intends to transform the world of medical diagnostics. Aron launched Orphidia in 2013 to provide affordable, point-of-care diagnostics that allow everyone to know their health. Orphidia has advanced the state-of-the-art with microfluidic-based medical diagnostics that are minimally invasive, replacing venous blood draws from a phlebotomist with a simple fingerstick that anyone can perform. Aron is a serial entrepreneur, whose background combines a PhD from the University of Cambridge and a focus on microfluidics and biotechnology with strong experience in professional management. At Protein Logic, a spin-out from Cambridge University that raised more than £3 million in initial funding to develop proprietary biomarker technology for the diagnosis and prediction of diseases, he served as COO. At WiseMed, where he was Co-founder, his team developed crowdsourced medical diagnostic technology as an affordable solution for improving healthcare in the developing world. Now, at Orphidia, Aron is providing the vision and leadership that will usher in the next generation of medical diagnostics, empowering everyone to know their health.
Follow Aron Rachamim:
About Senzo: Senzo is a deep-tech bio-med company developing testing products and IP.
Robert Habib
Chief Executive Officer of MiNA Therapeutics
Follow Robert Habib:
About MiNA Therapeutics: MiNA Therapeutics is a clinical-stage biotechnology company developing therapeutic medicines to harness gene activation mechanisms.
Anne Prener
President & CEO of Imbria Pharmaceuticals
Anne brings to Freeline over 25 years of experience in drug development and executive leadership across several therapeutic areas, with special focus on rare diseases and gene therapy. Anne most recently served as the CEO of Gyroscope Therapeutics, a preclinical gene therapy company focusing on ophthalmology, where she continues to serve as a non-executive Member of the Board. From 2014-2016, Anne was VP of Clinical Research Haematology and Global Therapeutic Area Head of Haematology in Baxalta, Boston, USA. In this role, she secured several new product approvals (US and EU). Before this, Anne held a number of senior leadership positions in a broad range of functional areas at Novo Nordisk, Denmark, leading global drug development programmes from research to commercialisation, and bringing several products to market globally. Anne has an MD from Copenhagen University and holds a PhD in Epidemiology.
Follow Anne Prener:
About Imbria Pharmaceuticals, Kaleido BioSciences: Imbria Pharmaceuticals is a biotechnology company with locations in San Diego, CA, and Boston, MA.
Hannah Sore
Founder and CEO of PharmEnable
Follow Hannah Sore:
About PharmEnable: PharmEnable has developed a rapid and cost effective way to identify better chemical starting points to drive the discovery.
Abdullah Sabyah
Founder and CEO of Rightangled
A scientist-entrepreneur and a healthcare professional, also a member of the British Heart Foundation Alliance, a member of the Clinical Pharmacogenomics Implementation Consortium in the US, and the inventor of a patent pending-technology for nucleic acid testing on a lateral flow assay (the patent is for a technology to detect DNA sequences in real-time).
Follow Abdullah Sabyah:
About Rightangled: Medtech specialised in Genetics, Blood and infection testing. Service is delivers through a platform that connects users with specialists.
Chas Taylor
Chief Executive Officer & Chairman of Respiratory Motion
Mr. Taylor has over 30 years of experience in the medical technology industry. Recently he was the CEO of Veryan Medical, a Co-founder and Director of Novate Medical, and a Director of BrightWater Medical. All three of these companies were acquired in the last three years. Previously, Mr. Taylor was the Co-founder of MedNova, which was acquired by Abbott Laboratories. Prior to founding and leading these companies, he had a long career with Bard Cardiovascular and General Surgical products where he had roles of increasing responsibility in general management and international sales and marketing.
Follow Chas Taylor:
About : Respiratory Motion ExSpiron is FDA and CE Mark cleared and non-invasively measures minute ventilation, the fundamental unit of breathing.
Mario Alberto Accardi
CEO and Co-Founder of Orexia
Life sciences executive and investor focused on starting, funding and running companies in the life sciences. Over a decade experience in the industry spanning fundamental research, venture capital and operational roles. I am now CEO and Co-Founder of Orexia and Inexia, two biotech companies founded with VC investor Medicxi and Sosei Heptares. I am also CEO and Co-Founder and inventor behind Orthonika, a medtech spin-out from Imperial College London.
Follow Mario Alberto Accardi:
About Orexia, Orthonika: Orexia aims to develop orally administered orexin positive modulators for the treatment of neurological diseases.
Graeme L. Smith
Chief Executive Officer of Lightpoint Medical
Graeme L. Smith is the Chief Executive Officer at Lightpoint Medical.
Follow Graeme L. Smith:
About Lightpoint Medical: Lightpoint Medical, a medical device company, develops intra-operative imaging technology that can detect cancer during surgery.
Bobby Gaspar
Chief Executive Officer of Orchard Therapeutics
Bobby is Professor of paediatrics and immunology at the UCL Institute of Child Health and Honorary Consultant in paediatric immunology at Great Ormond Street Hospital, London. He has a special interest in the treatment of severe primary immune deficiencies, including bone marrow transplantation, gene and cell therapy. He has led multiple clinical trials that have shown that gene therapy can successfully correct the genetic defect in immune deficiencies. Bobby is currently leading UK and European-wide initiatives for newborn screening in severe combined immune deficiency. He is Director of the Centre for Research in Rare Diseases in Children (CRRDC), a new academic and clinical facility that will open at Great Ormond Street in 2018.
Follow Bobby Gaspar:
About Orchard Therapeutics: Orchard Therapeutics is a biotechnology company dedicated to transforming the lives of patients through innovative gene therapies.
Zhangming Niu
Founder & CEO of MindRank AI
Follow Zhangming Niu:
About MindRank AI: MindRank is a developer of an AI-enabled drug-discovery platform intended to discover and develop next generation precision medicines.
James Noble
Founder & CEO of Adaptimmune
James Noble has served as our full-time Chief Executive Officer since March 2014 and part-time CEO from July 2008 to March 2014 and is one of our co-founders. From July 2008 until March 2014, Mr. Noble was also part-time CEO of Immunocore. Mr. Noble has 24 years of experience in the biotech industry. He has held numerous non-executive director positions, including at CuraGen Corporation, PowderJect Pharmaceuticals plc, Oxford GlycoSciences plc, MediGene AG, and Advanced Medical Solutions plc. Mr. Noble is also Deputy Chairman of GW Pharmaceuticals plc and a non-executive director of Immunocore Limited. Mr. Noble is qualified as a chartered accountant with Pricewaterhouse Coopers and spent seven years at the investment bank Kleinwort Benson Limited, where he became a director in 1990. He then joined British Biotech plc as Chief Financial Officer from 1990 to 1997. Mr. Noble was previously Chief Executive Officer of Avidex Limited, a privately held biotechnology company that was our predecessor, from 2000 to 2006. Mr. Noble holds an MA from the University of Oxford.
Follow James Noble:
About Adaptimmune, Advanced Medical Solutions, Curagen Corporation, MediGene, Oxford GlycoSciences, PowderJect Pharmaceuticals: Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
James Field
CEO & Founder of LabGenius
James is founder and CEO of LabGenius. James completed his PhD studies at Imperial College London where his research was focused on re-engineering protein nanocages for biotechnological applications. Prior to his PhD, James completed a BSc in Biology with Microbiology and an MRes in Systems and Synthetic Biology, at Imperial College London. James is an active member of the synthetic biology community having participated in the iGEM competition both as an undergraduate (2009), advisor (2011) and judge (2016). In 2017, James was awarded the BBSRC Innovator of the Year award for early career impact. James is also a fellow of the prestigious Synthetic Biology Leadership Excellence Accelerator Program (LEAP).
Follow James Field:
About LabGenius: LabGenius is a biopharmaceutical company developing protein therapeutics using a machine learning-driven evolution engine.
Dhivya Venkat
Co-Founder & Chief Executive Officer of Esya
Dhivya Venkat is the Co-Founder & Chief Executive Officer of Esya. University of Cambridge Degree NameGeneral ManagementField Of StudySuccessful Negotiation Strategies Dates attended or expected graduation2009
Follow Dhivya Venkat:
About Esya: Esya is a biotech company that measures, monitors, assist drug development, and pre-assess patient cohorts for treatment.
Paulina Chilarska
CEO & Founder of Cambridge Biolabs
Chilarska’s cutting-edge work at the University of Cambridge was funded by the prestigious 4-Year Wellcome Trust PhD award in Stem Cell Biology. Already at the age of 21 she worked with the Nobel Prize winner Sir Professor Paul Nurse on the cell cycle thus investigating the mechanisms underlying carcinogenesis. Dr Chilarska is an expert in the molecular basis of ageing and strongly believes that ageing is a disease which can be prevented and treated. She is currently wirting a book describing her revolutionary approach to Ageing Prevention and Ageing Reversal. She is fluent in five languages and has international consulting experience.
Follow Paulina Chilarska:
About Cambridge Biolabs: Biotech-meets-tech startup developing personalised skincare solutions
Tony de Fougerolles
Chief Executive Officer of Evox Therapeutics
Tony has been CEO of Evox Therapeutics since late 2017. He has 25 years of biotech R&D experience and has played a key role in developing and advancing three new drug modalities towards the market (mRNA, RNAi, Nanobodies). Previously, Tony was CSO of Ablynx, where he led the company’s non-clinical R&D operations and helped bring the 1st Nanobody drug, caplacizumab, to approval. Prior to Ablynx, Tony was the founding CSO at Moderna and pioneered modified mRNA as a new therapeutic modality for both rare diseases and as vaccines, including being the inventor of the mRNA chemistry and the foundational LNP formulations used in both the approved Moderna and Pfizer/BioNTech covid-19 vaccines. Prior to Moderna, Tony was among the first 6 employees at Alnylam and as VP Research helped develop RNAi as a new therapeutic modality, including overseeing the development of the now 1st approved LNP RNAi delivery system, and contributing to the development of several now approved RNAi drugs to treat life-threatening diseases. Tony has raised over $150m in equity financing, been the author on over $80m in grants, has over 60 scientific publications, and is an inventor on over 100 issued U.S. patents. He also serves on the Board of Walking Fish Therapeutics, is an advisor to and investor in multiple biotech companies, and is a Venture Partner at Ascension, a London-based venture capital firm. Lastly, he also volunteers his time with several non-profit organisations and charities. He earned his PhD in Immunology from Harvard University.
Follow Tony de Fougerolles:
About Evox Therapeutics: Evox Therapeutics is a biotechnology company that harnesses and engineer the natural trafficking capabilities of extracellular vesicles.
Michalis Papadakis
CEO & Co-Founder of Brainomix
Dr Michalis Papadakis is the CEO and co-founder of Brainomix. He leads the management team, commercial strategy, fund raising, and corporate partnerships. He has grown the company from the ground up, building the company’s global presence and has raised over £15 million of private investment and public funding. When he founded Brainomix he was the Scientific Director of the preclinical stroke lab at the University of Oxford. He has a BSc Honours in Biochemistry from Imperial College London and a PhD in neurosciences from UCL School of Pharmacy. He has been an invited speaker at international scientific and innovation conferences
Follow Michalis Papadakis:
About Brainomix: Brainomix specializes in the creation of AI-powered imaging biomarkers that enable precision medicine for better treatment decisions
Keiran Olivares Whitaker
Founder & CEO of Entocycle
Environmental engineer, YC alumni, five years expertise in rearing insects, passionate environmentalist, deep sea diver.
Follow Keiran Olivares Whitaker:
About Entocycle: Entocycle’s automated insect farm produces environmentally friendly insect protein to feed farmed animals.
Paulo Garcia
CEO & Co-Founder of Kytopen
Dr. Paulo A. Garcia co-invented the Flowfect™ technology while he was a Research Scientist at MIT. He is currently leading the development and commercialization efforts of the proprietary cell engineering platform for therapeutic and biotechnology applications.
Follow Paulo Garcia:
About Kytopen: Kytopen developer of a cell therapy platform for non-viral delivery of molecules into hard-to-transfect immune cells.
Ian Nicholson
Chief Executive Officer of F2G
Ian joined Advent in 2012 from Chroma Therapeutics Limited, a privately held oncology-focussed R&D company, where he served as Chief Executive Officer for eight years. Prior to joining Chroma, Ian was Senior Vice President, Business Development at Celltech Group plc, then the UK’s largest biotechnology company. He has extensive experience in licensing, mergers and acquisitions, and market development in the UK, Europe and the US. Ian has held a variety of senior commercial positions with Oxford Asymmetry International plc, Lonza AG and Amersham International plc and currently sits on the Boards of Consort Medical plc, Clinigen Group plc and is Non-Executive Chairman of Bioventix plc. Ian holds a B.Sc. (Hons.) degree from University College London and an MBA from Boston University. Ian is CEO of F2G Ltd and an advisor to NeRRe Therapeutics.
Follow Ian Nicholson:
About Advent Life Sciences, Amersham International, F2G: F2G discovers and develops novel drugs for the treatment of life-threatening fungal diseases.
Nick Morrell
CEO and co-Founder of Morphogen-IX
Nick is the British Heart Foundation Professor of Cardiopulmonary Medicine at the University of Cambridge, based in the Department of Medicine. He has 25 years of experience working in the field of pulmonary arterial hypertension (PAH), and is the Research Director of the National Pulmonary Hypertension Service at Papworth Hospital. His research spans clinical translational studies, experimental medicine, genetics, cell and molecular biology and preclinical models of disease. He has published over 200 papers in this field and is an internationally recognised authority on the pathobiology of PAH.
Follow Nick Morrell:
About Morphogen-IX, Papworth Hospital, University of Cambridge: MORPHOGEN-IX Limited is a drug discovery company founded in 2015 by Index Ventures to develop bone morphogenetic proteins
Susan Greenfield
Founder & CEO of Neuro-Bio
Follow Susan Greenfield:
About Neuro-Bio: Neuro-Bio is a British pharmaceutical company
Baroness Susan Greenfield
CEO & Founder of Neuro-Bio
Susan Greenfield is a neuroscientist, writer, and broadcaster. She has been awarded 30 Honorary Degrees from British and foreign universities and heads a multi-disciplinary research group exploring novel brain mechanisms linked to neurodegenerative diseases such Alzheimer’s and Parkinson’s. She is a Senior Research Fellow at Lincoln College, Oxford and has currently co-founded a biotech company developing a novel approach to neurodegenerative disorders (Neuro-Bio Ltd). In addition, she has published a neuroscientific theory of consciousness,’The Private Life of the Brain’ (2003) and developed a keen interest in the impact of modern technologies on how young people think and feel. This was discussed in her book, ‘ID: The Quest for Identity in the 21st Century’ (2008). In 1998 she received the Michael Faraday Medal from the Royal Society, was awarded a CBE in the Millennium New Year’s Honours List and was granted a non-political Life Peerage in 2001. In 2000 she was elected to an Honorary Fellowship of the Royal College of Physicians and in 2007 to an Honorary Fellowship of the Royal Society of Edinburgh. She was appointed Chancellor of Heriot Watt University in 2005. Further recognition of her work includes L’Ordre National de la Légion d’Honneur from the French Government, and the American Academy of Achievement Golden Plate Award, both received in 2003. Susan was also awarded the Australian Medical Research Society Medal in 2010. In 2011, Susan joined the Advisory Board of the Kusuma School of Biological Sciences at the Indian Institute for Technology, Delhi. In 2012, Susan was offered the Honorary Fellowship of the Institute of Risk Management and also became a Vice Patron of POWER International. Further on in 2012, Susan was selected to serve as the Parliamentary Patron of the Westminster Higher Education Forum, alongside of continuing to be a Parliamentary Patron of the Westminster Education Forum. Continuing through 2012, Susan bacame a Governor of The Florey Institute for Neuroscience and Mental Health and also started to suport the IAB (the International Advisory Board). In January 2014, she was included in the Debrett’s 500, “a recognition of the most influential and inspiring 500 people in Britain.”. Most recently, in July 2014, Susan was awarded as an Honorary Doctorate at Middlesex University.
Follow Baroness Susan Greenfield:
About Neuro-Bio: Neuro-Bio is a British pharmaceutical company
Alex Zhavoronkov
Founder & Chief Executive Officer of Insilico Medicine
Alex Zhavoronkov, PhD, is the founder and CEO of Insilico Medicine (insilico.com), a leader in next-generation artificial intelligence technologies for drug discovery, and biomarker development. He is also the founder and CEO of Deep Longevity, Inc, a global company developing a broad range of artificial intelligence-based biomarkers of aging and longevity. Since 2015 he invented critical technologies in the field of generative adversarial networks (GANs) and reinforcement learning (RL) for generation of the novel molecular structures with the desired properties and generation of synthetic biological and patient data. He also pioneered the applications of deep learning technologies for prediction of human biological age using multiple data types, transfer learning from aging into disease, target identification, and signaling pathway modeling. Under his leadership Insilico raised over $50 million in multiple rounds from expert investors, opened R&D centers in 6 countries and regions, and partnered with multiple pharmaceutical, biotechnology, and academic institutions. Prior to founding Insilico, he worked in senior roles at ATI Technologies (acquired by AMD in 2006), NeuroG Neuroinformatics, Biogerontology Research Foundation. Since 2012 he published over 130 peer-reviewed research papers, and 2 books including “The Ageless Generation: How Biomedical Advances Will Transform the Global Economy” (Palgrave Macmillan, 2013). He serves on the editorial boards of Aging Research Reviews, Aging, Trends in Molecular Medicine, Frontiers in Genetics, and co-chairs the Annual Aging Research, Drug Discovery and AI Forum (7th annual in 2020) at Basel Life, one of Europe’s largest industry events in drug discovery. He is the adjunct professor of artificial intelligence at the Buck Institute for Research on Aging.
Follow Alex Zhavoronkov:
About Deep Longevity, Insilico Medicine: Insilico Medicine develops an AI platform for drug development to treat cancer and age-related diseases.
Artin Moussavi
Chief Executive Officer of Leucid Bio
Artin Moussavi is the Chief Executive Officer at Leucid.
Follow Artin Moussavi:
About Epicore Health, Leucid Bio, Sainsbury Management Fellows: Leucid is progressing novel cart therapies that produce a better and more durable response.
Sergey Musienko
CEO of Atlas Biomed Group
Sergey Musienko is a technology expert with over a decade’s worth of experience, specifically in the health sector. He is the CEO of Atlas Biomed, the personalised health company. Sergey took time out to join the Silicon Valley think tank, Singularity University, in 2011. It was here that Sergey realised that the future was, in his words, “integrative personal omics profiles, which gather information about the body at a molecular level”. This insight led to him to found Atlas Biomed where he is currently the CEO. Here, he has put together a successful team that has developed two major products: the Atlas DNA Test and the Atlas Microbiome Test. These tests analyse how genes and gut bacteria influence various health traits like disease risk, nutrition, personal traits and physical activity, allowing people to take control of their health with actionable, scientifically proven lifestyle recommendations.
Follow Sergey Musienko:
About Atlas Biomed Group: The Atlas DNA and gut microbiome tests evaluate your health status and provide personalised recommendations to improve wellbeing.
Anthony Finbow
Chief Executive Officer of Eagle Genomics
Follow Anthony Finbow:
About 360Leaders, Eagle Genomics, Henley Business School, Solv: Eagle Genomics is a enterprise software solutions company to enable the management, orchestration and exploitation of life sciences data.
Benedikt von Thungen
CEO of Sanome
I’m the CEO and Co-Founder of Sanome, thanks for stopping by. My academic background is in biosciences. Along with experience in building software companies, I am so excited about the interface of the two fields and how they will change the healthcare industry. I started my entrepreneurial journey during my undergraduate degree and have since built multiple companies across renewable energy, enterprise software, AI, drug discovery, and healthcare. I love building and scaling winning teams in exceptional companies. My long-term vision is to build a human digital twin (a virtual representation of everyone’s biology & health) that allows us to predict any changes to someone’s health before they actually occur, thus enabling true preventative healthcare.
Follow Benedikt von Thungen:
About Sanome: Transforming diagnostics for all
John Beadle
Chief Executive Officer of Psioxus Therapeutics
Dr John Beadle was Entrepreneur in Residence at Imperial College London, where he helped to establish Myotec Therapeutics as a spin-out business. He became CEO of Myotec in late 2008, rapidly securing seed financing followed by a £5.6 million series A funding round from Imperial Innovations and Invesco Perpetual in early 2010. During this time, John was also Executive Chairman and CEO of Hybrid Biosystems, securing further seed financing for this Oxford based start-up. In 2010, John’s leadership of these two private companies led to their combination to form PsiOxus Therapeutics Ltd. John was previously the co-founder of the vaccine company PowderMed. In 2004 he helped to raise £20 million from leading UK and US Venture Capital Funds and was then Chief Medical Officer and board director leading to the trade sale of PowderMed to Pfizer for over US$300 million in 2006. John has previously held roles at PowderJect, Pfizer and Glaxo SmithKline where he was most recently VP of Global Medical Operations. John was trained in Medicine at the University of Witwatersrand and received his MBA with distinction from the London Business School.
Follow John Beadle:
About PowderMed, Psioxus Therapeutics: Psioxus Therapeutics is a cancer gene therapy company delivers medicines of value to patients with cancer.
Mick Crosthwaite
Chief Executive Officer of Hallmarq Veterinary Imaging
Follow Mick Crosthwaite:
About Hallmarq Veterinary Imaging: Hallmarq Veterinary Imaging is a global leader in innovative diagnostic imaging.
David Atkins
CEO of Congenica
Dr Atkins has over 25 years’ experience as a global leader in a broad range of diagnostics and healthcare businesses. He has held senior positions in R&D, business development, operations and sales and marketing. He has extensive commercial experience in markets in North America, EMEA, Asia and Latin America. Prior to joining Congenica, Dr Atkins was CEO of Synevo, a clinical diagnostic laboratory service business operating across Germany and Eastern Europe. Past roles also include global head of the Advanced Staining pathology business unit for Leica Biosystems, a Danaher Company. Dr Atkins also has over 20 years’ experience with Johnson & Johnson’s Medical Device and Diagnostic businesses in R&D and business development and in senior international commercial roles.
Follow David Atkins:
About Congenica: Congenica is a biotechnology company that provides a diagnostic decision support platform.
Andrew Hopkins
Co-Founder and CEO of Exscientia
Andrew spent 10 years at Pfizer, where he was responsible for establishing new research foci including the concepts of druggability and network pharmacology. Andrew has raised a total of $50 million for academic and commercial research activities in his continuing role as Chair of Medicinal Informatics at the University of Dundee. He is the author of some of the most highly cited papers in modern drug discovery.
Follow Andrew Hopkins:
About Exscientia, Kinetic Discovery Ltd.: Exscientia is a pharmatech company that uses an end-to-end AI platform to design and discover new drugs.
Daniel L. Cohen
CEO and Co-Founder of 3D Bio Holdings
Daniel L. Cohen is the Chief Executive Officer and Director at 3D Bio Holdings.
Follow Daniel L. Cohen:
About 3D Bio Holdings: 3D Bio Holdings is a company that specializes in regenerative medicine and devices.
Emilio Sanz Pereiras
CEO of Acurable
Emilio is a serial entrepreneur and leads Acurable’s strategy, operations and commercialisation activities. Emilio spent the last 15 years building 3 successful start-ups across Europe and Asia, where he learned first hand how to successfully commercialise highly innovative technologies and how to to scale start-up operations in both B2B and B2C industries. Originally from Spain, Emilio holds a MSc in Electrical Engineering from Telecom ParisTech, a MSc in Computer Science from the Polytechnic University of Madrid and an MBA from London Business School.
Follow Emilio Sanz Pereiras:
About Acurable: The first wearable medical device able to accurately diagnose and manage respiratory conditions at home
Dr. Danuta Jeziorska
CEO & Co-Founder of Nucleome Therapeutics
Danuta Jeziorska is the CEO & Co-Founder at Nucleome Therapeutics.
Follow Dr. Danuta Jeziorska:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Dr. Danuta Jeziorska
CEO & Co-Founder of Nucleome Therapeutics
Danuta Jeziorska is the CEO & Co-Founder at Nucleome Therapeutics.
Follow Dr. Danuta Jeziorska:
About Nucleome Therapeutics: Nucleome Therapeutics is decoding the dark matter of the human genome to uncover novel ways to treat diseases
Martin Murphy
Co-Founder & Chief Executive Officer of Syncona Partners LLP
Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 with The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of four Syncona companies: Achilles, Autolus, Blue Earth and OMass Therapeutics and continues to hold Board positions at these companies. Previously, he was a partner at MVM Life Science Partners LLP, a venture capital company focused on life science and healthcare, where he led their European operations. Martin has also held roles with 3i Group plc and McKinsey & Company. He has a PhD in Biochemistry from the University of Cambridge.
Follow Martin Murphy:
About Syncona Partners LLP: Syncona Partners LLP is a healthcare company focused on investing in and building global leaders in life science.
Chris Torrance
Co-Founder and CEO of PhoreMost
Chris has significant oncology research and development experience, including six years as a senior manager at Cambridge-based pharmaceutical company, Vernalis. His principle expertise lies in cancer cell biology and drug discovery. In this field, he has led project teams taking drug targets from inception through to hit identification, lead optimisation and into preclinical studies. Chris holds a PhD from East Carolina University and completed a Post-Doctoral position in the world renowned oncology laboratory of Professor Bert Vogelstein (Johns Hopkins University) where he pioneered the use of X-MAN™ cancer models in high-throughput screening and drug discovery.
Follow Chris Torrance:
About PhoreMost: PhoreMost is a new-model drug discovery company based in Cambridge, UK.
Keith Blundy
CEO of Storm Therapeutics
Follow Keith Blundy:
About Storm Therapeutics: Targeting pathways that modify RNA to deliver novel cancer therapeutics
Paul Cowan
Founder , Chairman & Chief Executive Officer of Quotient Biodiagnostics
Paul Cowan is our Chief Executive Officer and Chairman of our Board of Directors. Mr. Cowan founded us through the acquisition of Alba Bioscience in 2007. He has a broad range of healthcare industry experience gained through over 15 years of employment within industry and investment banking. Previously, Mr. Cowan served as the Chief Financial Officer of Inveresk Research Group, a global contract research organization that was acquired by Charles River Laboratories in 2004. Prior to joining Inveresk in 2001, Mr. Cowan was a senior executive within the Investment Banking department of Bear Stearns & Co., where he led the European biotechnology practice. Prior to Bear Stearns, Mr. Cowan was a senior executive within the Investment Banking department of Morgan Grenfell (acquired by Deutsche Bank in 1990). Mr. Cowan received a Bachelor of Business in accounting from Queensland University of Technology.
Follow Paul Cowan:
About Quotient Biodiagnostics: Quotient Biodiagnostics develops and manufactures products for use in transfusion diagnostics.
Vid Stojevic
Co-Founder and CEO of Kuano
Vid has spent the past 10 years working on string theory and tensorial methods in quantum physics and has held postdocs at UCL and the University of Vienna with pioneers in these fields. He has publications in numerous high impact journals.
Follow Vid Stojevic:
About Kuano: Kuano provides innovative quantum and AI solutions for drug discovery and design.
Chris Martin
CEO of ADC Therapeutics
Chris Martin, DPhil, is the former CEO and co-founder ADC Therapeutics, a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates.
Follow Chris Martin:
About ADC Therapeutics: ADC Therapeutics develops antibody drug conjugates and non-antibody drug conjugate products.
David Sibbald
CEO and Co-Founder of Aridhia Informatics
David Sibbald is the co-founder and CEO of Aridhia, a health data science company which develops and runs a cloud-enabled Digital Research Environment for clinical research, precision medicine and healthcare applications. David is the Founder and Trustee of the Kate MacAskill Foundation, a charitable organisation providing education, care and micro-enterprise funding for children and young adults in the developing world and is Chairman of the Johari Foundation. He has been awarded honorary doctorates from Glasgow University, Glasgow Caledonian University, the University of Paisley and the University of Strathclyde for services to Scottish science and philanthropy. He is a Fellow of the Royal Society of Edinburgh, Scotland’s National Academy of Science and Letters. In the 2010 New Year Honours List, David was awarded an OBE for charitable services in Scotland and overseas.
Follow David Sibbald:
About Aridhia Informatics, Kate MacAskill Foundation: Aridhia informatics provides biomedical informatics and analytics services to improve the management of chronic diseases.
Thomas Weaver
Founder & CEO of PetMedix
Tom holds a PhD in Experimental Oncology and has served in a variety of research, technology development and commercial roles. He has a proven track record of creating value in highly successful start-up companies applying genome-based technologies and contract services for fundamental research, clinical, and drug discovery purposes. He has also led large infrastructure programs in genomics and animal model genetics, serving as a Director at the Medical Research Council (Oxford, UK). He trained at the University of Cambridge and MRC Lab for Molecular Biology (Cambridge, UK), and the University of Wisconsin Medical School, (Madison, USA).
Follow Thomas Weaver:
About PetMedix: PetMedix is a pet therapeutics startup.
Jonathan O’Halloran
CEO of QuantuMDx Group
Inventor of QuantuMDx’s proprietary nucleic acid preparation, amplification and detection technology with over 12 years in scientific research, biotechnology & clinical laboratories.
Follow Jonathan O’Halloran:
About QuantuMDx Group: QuantuMDx is a medical devices company developing handheld and portable diagnostic, genomic sequencing, and proteomic platforms.
Kamil Tamiola
Chief Executive Officer of Peptone
I am a physicist, founder and CEO of Peptone Ltd.
Follow Kamil Tamiola:
About Peptone: Peptone is a UK-based startup that is helping pharmaceutical companies unravel the secrets of proteins.
Johannes Solzbach
CEO & Co-Founder of Clustermarket
Johannes Solzbach has been Chief Executive Officer and Director at Clustermarket LTD.
Follow Johannes Solzbach:
About Clustermarket: One lab management platform that brings people, equipment and data together – no matter where they are.
Martin-Immanuel Bittner
Co-Founder & CEO of Arctoris
Martin-Immanuel Bittner MD DPhil is a clinician-scientist and life sciences entrepreneur. He is a Rhodes scholar, an active member of several leading cancer research organisations, and an elected member of the Young Academy of the German National Academy of Sciences. Martin is a Co-Founder & CEO of Arctoris, the world’s first fully automated drug discovery platform.
Follow Martin-Immanuel Bittner:
About Arctoris: Arctoris is a tech-enabled platform company in biotechnology, combining robotics & data science to accelerate drug discovery.
Victor Dillard
Founder , COO & CEO of Desktop Genetics
A former chemical engineer keen on seeing personalized treatment realized, Victor has spent the past three years leading Desktop Genetics’ business development and CRISPR genome-editing initiatives. He has closed several partnerships with leading life science companies, placing Desktop Genetics at the forefront of CRISPR therapeutics research. Informed by his previous experience at P&G, GlaxoSmithKline, Flagship Ventures, Victor believes that software will be the key to unlocking the full potential of biotech R&D. He holds MEng, Chemical Engineering from Imperial College London and an MPhil in Bioscience Enterprise from the University of Cambridge.
Follow Victor Dillard:
About Desktop Genetics: Desktop Genetics is an international company to help researchers discover and treat the root genetic causes of human disease.
AF_initDataCallback({key: \’ds:1\'” alt=”” class=”wp-image-14850″ width=”154″ height=”152″/>Mike Westby
CEO of Centauri Therapeutics
Mike Westby is the Chief Executive Officer at Centauri Therapeutics Limited since September 2015.
Follow Mike Westby:
About Avvinity, Centauri Therapeutics: Centauri Therapeutics is a UK-based biotechnology company focused on the discovery and development of life threatening diseases.
Timothy Brownstone
Founder & CEO of KYMIRA Sport
Follow Timothy Brownstone:
About KYMIRA Sport: KYMIRA Sport is developing a range of performance and recovery enhancing sportswear.
Rasmus Hansen
Co-founder & CEO of Airfinity
Follow Rasmus Hansen:
About Airfinity: Airfinity is a science information and analytics company
Jason Mellad
CEO of Start Codon
Follow Jason Mellad:
About Start Codon: Translating disruptive research into successful start-ups, the Cambridge way
Julian Melchiorri
Founder and CEO of Arborea
Julian Melchiorri is an inventor, engineer, and entrepreneur recognized by Forbes as a leading EU social entrepreneur under 30 years of age. Julian is the Founder and CEO of Arborea, a food-tech start-up that applies break-through proprietary biological and chemical engineering technology platforms to produce healthy food ingredients at low-cost and massive scale to help food producers build a food system where everyone eats well. Earlier in his career, Melchiorri designed and engineered both products and manufacturing processes for major Italian lighting production company and for the London high-tech collective ‘’Random International’’, making technology-driven interactive experiments and large scale installations, utilizing a multitude of technologies such as robotic, sensing and hydraulic technologies.
Follow Julian Melchiorri:
About Arborea: Arborea is industrialising photosynthesis to expand the world’s food supply
Pravin Badhe
Founder & CEO of SwaLife Biotech
Pravin Badhe has over 12 years of experience in Pharmaceutical field. He has expertise in target discovery and lead identification and has experience in drug repurposing in rare disease such as progeria. He is a Pharmacist and has PhD in life science. In PhD he has discover five novel small molecules from plants. He is an experience scientist and has got expertise in pharma wholesale, retail sales, marketing and general management. He has held number of positions with both research and development. As research assistant, he led cross-functional teams in the delivery of standardise plant extracts and fractions for cosmetic purpose. He is founder and CEO of Swalife Biotech and is responsible for developing and managing financial systems and policies. He is responsible in recruiting, communicating values and developing education opportunities. He will represent the company in strategic meetings and will be responsible for preparing financial reports, budgets, and financial statements for the organization. He is advisor in Shree Om Medico pharma distributor company in India. He brings extensive experience of growing organisations across all aspects of the biotech environment.
Follow Pravin Badhe:
About SwaLife Biotech: SwaLife Biotech discovers small molecules from plants for cosmetics and synthesizes novel anticancer plant alkaloids.
Philip M. Toleikis
President & CEO of Sernova
Dr. Toleikis is President and Chief Executive Officer of Sernova Corp since April 2009. From 2006 until 2009, Dr. Toleikis consulted for multiple device, combination product and pharmaceutical companies. From 1996 to 2006 he held multiple roles at Angiotech Pharmaceuticals, Inc. including Vice President, Research and Development – Pharmacology and Drug Screening where he built a product development team of over 50 scientists and was responsible for multiple corporate and academic product development collaborations. While at Sernova, Dr. Toleikis has secured over $60 million in various forms of financings, including equity raises and multiple non-dilutive grants and has been responsible for negotiating a worldwide exclusive license with UHN and University of Miami for its stem cell derived technologies as well as developing business relationships and or collaborations with multiple pharmaceutical and academic institutions involving its Cell Pouch™ device and cell technologies. Dr. Toleikis is an author of over 100 patent applications ande issued patents, and multiple scientific publications involving transplantation, metabolic, cardiovascular, oncology, and autoimmune disease. He obtained his Ph.D. in Medicine, Pharmacology and Therapeutics from the University of British Columbia, his M.Sc. at the University of Michigan and B.A. at the University of Vermont.
Follow Philip M. Toleikis:
About Sernova: Sernova develops regenerative medicine therapeutic technologies for treatment of chronic metabolic diseases.
Graham Ellis
CEO of Ocean Harvest Technology Limited
Follow Graham Ellis:
About GLG, Ocean Harvest Technology Limited: Ag-Tech company developing prebiotic solutions for animals and humans using macroalgal sources
Colin Story
Co-Founder & CEO of OxSonics Therapeutics
Colin Story brings over 20 years of medical technology and life sciences industrial experience, the majority held in commercial roles. After graduating with a BSc degree in Biological Sciences and a PhD in Molecular Biology he started his career at Amersham plc (now GE Healthcare) in 1997. Initially he held Product Development and Project Management roles in R&D and then latterly held a commercial role where he managed a £20m product portfolio. In 2005 he joined Isis Innovation Ltd, where he initiated, led and concluded a range of multi-£m transactions. In 2008 he went on to recruit and direct a Business Development team that managed over 200 medical science innovations emanating from Oxford University. In 2011 he joined OrganOx Ltd as Operations Director where he handled all operational and contractual aspects of the business that saw the company take a class III medical device from prototype into, and successfully through, first in man clinical trials. In January 2014 he became Co-Founder, Executive Director and the Chief Executive Officer of OxSonics® Ltd.
Follow Colin Story:
About OrthoSon, OxSonics Therapeutics: OxSonics® Therapeutics’ proprietary drug delivery platform technology, SonoTran®
Gilad Gershon
CEO of Tropic Biosciences
Gilad Gershon is an experienced AgriTech entrepreneur and venture capital investor, including at Pontifax Global Food and Agricultural Technology Fund and Grovepoint Capital. He is a former Navy Ship Commander in the Israel Defense Forces (Ret. Lieutenant Colonel), and holds a Bs.C. in Industrial Engineering (with Honors) from Tel Aviv University and an MBA (with Honors) from the UCLA Anderson School of Management.
Follow Gilad Gershon:
About Tropic Biosciences: Tropic Biosciences is a pioneering leader in the development of novel high-performing commercial tropical crop varieties and traits.
Alexander Patto
Chief Executive Officer of Waterscope
Alexander Patto and Tianheng Zhao founded Waterscope in 2015, since which Alexander has been serving as its chief executive officer.
Follow Alexander Patto:
About Waterscope: Waterscope is a not-for-profit impact-defined company based in Cambridge.
Grant Aarons
Co-Founder & CEO of FabricNano
Follow Grant Aarons:
About FabricNano: FabricNano is a cell-free biomanufacturing company that develops a DNA-based flow reactor to unlock the future of biochemistry.
Simos Kedikoglou
Chief Executive Officer of Impulse Dynamics
Simos Kedikoglou is the CEO of Impulse Dynamics since 2013 and serves on the Company’s Board of Directors.He was previously CEO of MedInvest, an Israeli Medical Technology Incubator overseeing 10 portfolio companies with responsibility for their clinical and commercial strategy, technology development and debt and equity financing. He has also served as Corporate Vice President of Business Development for Boston Scientific responsible for acquisitions, licensing and distribution deals in the US, Europe and Asia and an Associate Partner with McKinsey & Company in the US advising clients on acquisitions in pharmaceuticals and medical devices. Simos holds a Medical Degree from the University of Athens, Greece, an MBA with distinction from Harvard Business School as well as a Master’s in Public Health from Harvard University, and he is a CFA Charterholder.
Follow Simos Kedikoglou:
About Impulse Dynamics: Impulse Dynamics is a medical device company dedicated to offering innovative solutions for treatment of Chronic Heart Failure (CHF).
Ingvar Helgason
Co-founder and CEO of VitroLabs
Ingvar Helgason is Co-founder and CEO at VitroLabs Inc.
Follow Ingvar Helgason:
About VitroLabs: We work with nature to create real leather from cells, that’s slaughter-free and better for the environment.
Andrew Crockett
Founder & CEO of KalVista Pharmaceuticals
Andrew Crockett is a Founder & CEO at KalVista Pharmaceuticals.
Follow Andrew Crockett:
About KalVista Pharmaceuticals, Vantia Therapeutics: KalVista Pharmaceuticals is an ophthalmology company focused on developing drugs for the treatment of diabetic macular edema (DME).
George Frodsham
Founder & CEO of MediSieve
George Frodsham founded MediSieve after being awarded his PhD in biochemical engineering from University College London (UCL), during which he developed the magnetic blood filter. As well as being a physicist and engineer, George is an entrepreneur. George was awarded a BBSRC Enterprise Fellowship from the Royal Society of Edinburgh in 2014. Since 1996, only 180 individuals have benefited from this highly competitive and prestigious programme. George has also completed the Entrepreneurship Summer School programme at the London Business School. This equipped him to research target markets and industries and turn his visions into viable businesses.
Follow George Frodsham:
About MediSieve: MediSieve is a therapeutics company developing a platform technology for the treatment of blood-borne diseases.
Ali Afshar
CEO, Co-founder of Mytos
Ali is co-founder of Cytera CellWorks.
Follow Ali Afshar:
About Mytos: Mytos is building a fully-automated cell manufacture platform for Pharma
Himanshu Kataria
Founder, CEO and Managing Director of CLYZ Labs
Himanshu is an experienced NHS Academic Clinician with emergency medicine background (>10 years clinical experience). Himanshu has substantial experience in setup and delivery of clinical research trials, as a specialty lead within Clinical Research Network for the whole of North West Coast of England delivering research in >23 NHS Partner organisations. Himanshu is an MBBS, MBBS, MRCSed (A&E), MRCEM, FRCEM, ALS Instructor. With a number of years in both clinical and research experience, Himanshu has held various consultancy posts in notable hospitals/medical facilities such as Whiston Hospital in Merseyside. He also held the Special Group Lead position within the Clinical Research Network – North West Coast: Research Delivery arm of the NIHR (National Institute of Health Research). In addition to his qualifications as a Medical Doctor, Himanshu has held a number of entrepreneurial roles over the past few years in bio-medical companies such as Indu Stem Cell Technology Plc, and Transgenex Inc in the USA. Dr Kataria is familiar with financial management of the business owing to his experience in Clinical Finance Limited which advised for fundraising for Indu Stem Cell Technology PLC. He continues to serve as a director for Indu Stem Cell Technology PLC.
Follow Himanshu Kataria:
About CLYZ Labs: CLYZ Labs are developing a testing service to select the best drug therapy for personalised cancer treatment.
Ruchi Sharma
Founder and CEO of Stemnovate
Ruchi Sharma is driven by her passion for taking the benefits of research, and applying them to products and technology in order to make a significant and positive difference in the real world. Alongside over ten years experience in stem cell research, physiology, and biotechnology, Ruchi Sharma obtained a PhD from the world-renowned Roslin Institute at the University of Edinburgh, followed by a post-doctorate in the exciting field of cellular reprogramming at the University of Cambridge.
Follow Ruchi Sharma:
About Stemnovate: Drug Screening and Safety Testing Platforms
Olga Kubassova
Chief Executive Officer of IAG, Image Analysis Group
Olga Kubassova is the Founder and CEO at IAG, mage Analysis Group. Mathematician with 10+ years expertise in actively managing innovation in life science companies, asset positioning, strategy and capital rising. Extensive expertise and domain knowledge in identifying innovative approaches to clinical research, disruptive technology platforms and novel therapeutics. Olga is a renowned healthcare innovator and biotech investor, with passion for improving people’s health.
Follow Olga Kubassova:
About Analytics Ventures, Bio Capital Impact Fund, European Commission, IAG, Image Analysis Group: IAG, imaging expert company helps to accelerate novel drug development by using the right analytical tools and modern trial infrastructure.
Ozgur Tuncer
CEO & Executive Director of Stablepharma Ltd
Ozgur Tuncer CEO & Executive Director – two decades of experience in the biopharmaceutical industry including working for blue chip companies such as Pfizer, IQVIA and Pharmacia. Most recently, he was Global Vice President in IQVIA, and strategic adviser to life sciences investors. In addition to his role in Stablepharma, Özgür is an Investment Partner with Ascension Ventures.
Follow Ozgur Tuncer:
About Stablepharma Ltd: An innovative Biotech, developing a wide range of reformulated thermostable and fridge free StablevaX vaccines
Jamie Denison-Pender
CEO of Prescient Healthcare Group
Jamie is Prescient Healthcare Group’s CEO and a career consultant, having spent more than 20 years growing and managing healthcare-focused consultancies. In 2007, he became managing director of a global competitive strategy consultancy and led the company’s transition from an industry generalist to a biopharmaceutical specialist. He rebranded the company to Prescient in 2010 and led a management buyout in 2014. Jamie remains actively involved with our clients, mainly focusing on strategic simulation workshops and mature brand strategies.
Follow Jamie Denison-Pender:
About Prescient Healthcare Group: Prescient Healthcare Group was founded in London in 1995, originally specializing in competitive insights.
Ibraheem Mahmood
CEO of DrugDev
Ibraheem Mahmood is the president and CEO of DrugDev.
Follow Ibraheem Mahmood:
About AMO Pharma, DrugDev: DrugDev is a cloud technology based solutions that enable better clinical trials.
Robert Johnson
CEO of Adrestia Therapeutics
Robert Johnson is the Chief Executive Officer of Adrestia Therapeutics.
Follow Robert Johnson:
About Adrestia Therapeutics: Adrestia is developing therapeutics that work in an entirely new way – restoring the biological balance in damaged, diseased or dying cells
Richard Pither
CEO of Cytox
Dr Richard Pither is CEO of Cytox Ltd. Richard has been involved in the development diagnostic and therapeutic pharmaceutical products for more than twenty years. He has held senior R&D and leadership positions in global Pharmaceutical companies including GE Healthcare (Medical Diagnostics), UCB-Celltech, Lorantis and Amersham plc. During this time, he was involved in the development of a novel 18F-PET radiopharmaceutical for imaging amyloid deposition in the brains of Alzheimer’s Disease patients for more than ten years. Richard has a BSc in Cellular and Molecular Pathology from Bristol University. His PhD, also at Bristol, was gained in the field of immunology and vaccine design, followed by post-doctoral research at Harvard.
Follow Richard Pither:
About Cytox: Cytox have developed a simple genetic based blood test for the assessment of risk and diagnosis of Alzheimer’s Disease.
Joanna Gould
CEO of VisusNano
Joanna obtained her PhD in developmental Neuroscience at the University of Southampton. After her MRes Joanna had a career change and went into corporate banking at Bank of America before deciding to come back to science. Joanna has also worked in research and development at an SME.
Follow Joanna Gould:
About VisusNano: Revolutionising Treatment for Cataracts
